Millennium Management LLC Acquires 842,814 Shares of Horizon Pharma PLC (HZNP)

Millennium Management LLC boosted its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 299.2% in the 1st quarter, Holdings Channel reports. The firm owned 1,124,465 shares of the biopharmaceutical company’s stock after purchasing an additional 842,814 shares during the period. Millennium Management LLC’s holdings in Horizon Pharma were worth $15,967,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Trexquant Investment LP bought a new stake in Horizon Pharma in the first quarter worth $2,008,000. American Century Companies Inc. lifted its stake in Horizon Pharma by 158.5% in the first quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock worth $10,036,000 after purchasing an additional 433,359 shares during the last quarter. Systematic Financial Management LP bought a new stake in Horizon Pharma in the first quarter worth $1,428,000. Federated Investors Inc. PA lifted its stake in Horizon Pharma by 140.8% in the first quarter. Federated Investors Inc. PA now owns 639,867 shares of the biopharmaceutical company’s stock worth $9,086,000 after purchasing an additional 374,107 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in Horizon Pharma in the fourth quarter worth $7,443,000. 84.99% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Brian K. Beeler sold 17,931 shares of the business’s stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $16.11, for a total transaction of $288,868.41. Following the transaction, the executive vice president now owns 110,524 shares in the company, valued at $1,780,541.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Timothy P. Walbert sold 83,353 shares of the business’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $16.17, for a total transaction of $1,347,818.01. The disclosure for this sale can be found here. Insiders have sold 116,717 shares of company stock worth $1,907,999 in the last quarter. 3.90% of the stock is owned by corporate insiders.

Horizon Pharma opened at $16.80 on Thursday, Marketbeat Ratings reports. Horizon Pharma PLC has a 12-month low of $11.17 and a 12-month high of $18.23. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 14.24, a PEG ratio of 1.01 and a beta of 1.37. The company has a debt-to-equity ratio of 2.17, a quick ratio of 1.50 and a current ratio of 1.56.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.08). Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The firm had revenue of $223.88 million during the quarter, compared to analysts’ expectations of $232.05 million. During the same quarter in the previous year, the firm posted $0.21 EPS. Horizon Pharma’s revenue was up 1.4% compared to the same quarter last year. equities analysts predict that Horizon Pharma PLC will post 1.41 EPS for the current year.

Several analysts have weighed in on HZNP shares. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price objective on shares of Horizon Pharma in a research report on Wednesday, March 14th. BidaskClub cut shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 22nd. Zacks Investment Research cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 4th. Finally, Mizuho restated a “buy” rating and issued a $18.00 price objective on shares of Horizon Pharma in a research report on Monday, May 7th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Horizon Pharma currently has an average rating of “Buy” and a consensus price target of $19.40.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply